A new study drops, and predictably, the headlines follow. Cannabis triples your lung cancer risk. Heavy users beware. Smoke at your peril. The coverage makes it sound like rolling a joint is roughly equivalent to gargling asbestos, and the average reader is left with one clear takeaway: marijuana will kill you.
There are many ways that the current wave of psychedelic research marks a dramatic breakthrough in society and culture: we no longer see these substances as recreational drugs, but powerful medicines in the realms of mental health, well-being, and neuroscience.
The Wall Street Journal's Future View recently asked college students whether marijuana should be legal. Several of them wrote thoughtful pieces. A few of them wrote arguments that collapse the moment you apply them consistently. I respect the exercise, and I respect that these are young people working through genuinely complex policy questions. But bad arguments don't improve with politeness, so let's get into it.
On May 14, 2026, the U.S. Army published an article titled 'Breaking Down Cannabinoids: How They Compromise Readiness.' The piece, written by two staffers from the Directorate of Prevention, Resilience and Readiness, runs through the standard arguments: cannabinoids impair judgment, Delta-8 can cause false positives, CBD is banned regardless of what your state law says, zero tolerance is the policy, full stop.
Vegan Delta 9 gummies are edible hemp-derived THC products made without animal-based ingredients. Traditional gummies often contain gelatin, which manufacturers usually source from animal collagen. Vegan gummies replace gelatin with plant-based alternatives like pectin, a natural fiber commonly derived from fruits.
The Trump administration had an opening. The hemp market proved the concept. The polling supported the move. The fiscal argument was there. Instead, the White House published a 195-page document that reads like it was written in 1988, invokes psychosis studies with contested methodology, and affirms the recriminalization of a $28 billion industry that was, by any reasonable measure, working.
Medical marijuana is becoming increasingly mainstream across the United States, with millions of patients now using cannabis to manage conditions such as chronic pain, anxiety, PTSD, insomnia, epilepsy, and cancer-related symptoms. But as legalization expands and dispensaries become easier to access, an important issue is getting lost in the excitement: physician guidance still matters.
Start with the most obvious one. The pharmaceutical industry loses, by some estimates, around $10 billion annually in markets where medical cannabis is legal. Patients substitute cannabis for opioids, sleep aids, anti-anxiety medications, and antidepressants. Not all patients, and not always — but enough to show up in the revenue reports.
When a brand describes its CBD flower as lab tested, that phrase should carry real weight but not all testing is created equal. The gold standard is third-party testing by an ISO-certified laboratory. Third-party means the lab has no financial relationship with the brand whose products it's testing.
The 2026 awards made one thing clear: growers are done with mystery clones from anonymous sellers. Get Seeds Right Here earned #1 because it gave growers the strongest overall package: catalog, reputation, ordering experience, and a clear long-term commitment to the cannabis clone space. The rest of the top five earned their spots doing the same work at a slightly smaller scale.
